Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 6.27B 5.48B 5.05B 4.67B 8.86B 598B 9.01B 60.4B 23.72B 294B 23.52B 23.01B 1,012B P/E 2026 *
70.8x
P/E 2027 * 37.4x
Enterprise Value 6.27B 5.48B 5.05B 4.67B 8.86B 598B 9.01B 60.4B 23.72B 294B 23.52B 23.01B 1,012B EV / Sales 2026 *
21.6x
EV / Sales 2027 * 16.7x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day-1.97%
1 week-1.04%
Current month+0.05%
1 month+27.39%
3 months+54.32%
6 months+53.03%
Current year+67.26%
1 week 310.67
Extreme 310.67
326.63
1 month 245
Extreme 245
326.63
Current year 175.89
Extreme 175.89
326.63
1 year 120.68
Extreme 120.68
326.63
3 years 49.24
Extreme 49.24
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 66 05/12/2022
Director of Finance/CFO 47 21/05/2015
Director of Finance/CFO 56 01/11/2022
Director TitleAgeSince
Chairman 76 01/03/2003
Director/Board Member 57 27/09/2006
Director/Board Member 66 01/03/2007
Date Insider Type Main position Quantity % Market Cap.
07-01Fiscal year

General Counsel

15,000 0.0748%
06-30Others

Chief Financial Officer

17 0.0001%
06-30Others

Chief Executive Officer

132 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
-1.97%-1.04%+153.03%+352.74% 6.27B
-2.33%-2.09%+50.33%+162.29% 1,060B
-0.82%-2.30%+62.97%+61.11% 619B
-0.73%-4.98%+27.22%+84.46% 438B
+0.33%-1.17%+27.98%+26.90% 333B
-0.02%-2.85%+25.27%+44.88% 282B
-3.89%-11.22%+20.78%+26.07% 267B
+0.66%-1.42%-29.26%-39.30% 218B
-0.06%-2.88%+20.98%+61.70% 196B
-3.72%-1.10%+13.35%+71.53% 161B
Average -1.00%-3.03%+37.26%+85.24% 358.02B
Weighted average by Cap. -0.57%-2.95%+35.49%+81.74%

Financials

2026 *2027 *
Net sales 290M 254M 234M 216M 410M 27.68B 417M 2.8B 1.1B 13.64B 1.09B 1.07B 46.87B 376M 329M 303M 280M 532M 35.88B 541M 3.63B 1.42B 17.67B 1.41B 1.38B 60.76B
Net income 94.92M 83.02M 76.58M 70.73M 134M 9.05B 136M 915M 359M 4.46B 356M 349M 15.33B 183M 160M 147M 136M 258M 17.42B 263M 1.76B 691M 8.58B 686M 671M 29.5B
Net Debt - -
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Employees
47
Date Price Change Volume
10/07/26 $316.24 -1.97% 148,576
09/07/26 $322.61 +2.45% 583,112
08/07/26 $314.88 -1.42% 404,996
07/07/26 $319.43 -0.31% 316,475
06/07/26 $320.42 +0.27% 349,436
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
316.24USD
Average target price
297.50USD
Spread / Average Target
-5.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGND Stock